A newly published study funded by the National Institutes of Health has revealed surprising findings about the relationship between testosterone and glioblastoma, one of the deadliest forms of brain cancer. Researchers at Cleveland Clinic discovered that testosterone and other male hormones may actually help slow tumor growth in men, challenging long held assumptions about hormones and cancer development.
The findings, published in the journal Nature, could open the door to future treatments targeting hormone pathways in brain cancer patients.
Glioblastoma is an aggressive type of brain tumor that affects thousands of people every year. It is known for rapid progression, difficult treatment options, and poor survival outcomes. Scientists have long observed that glioblastoma appears more frequently in men than women, leading many experts to suspect male hormones may contribute to the disease.
However, this new research suggests the opposite may be true.
According to the study, reducing androgen hormones such as testosterone in male laboratory models actually accelerated tumor growth. Researchers found that hormone loss triggered inflammation inside the brain and activated stress related hormonal systems, creating an environment where tumors could grow more easily.
This discovery could significantly change how scientists understand the connection between hormones and brain cancer.
The research team focused on the brain’s unique immune environment. Unlike other organs, the brain tightly controls which immune cells can enter its tissues. Scientists discovered that testosterone appears to help regulate this delicate balance.
When androgen levels dropped, a neuroendocrine system known as the hypothalamus pituitary adrenal axis became highly active. This led to increased production of stress hormones and stronger immune suppression within the brain.
As a result, fewer immune cells could reach and attack the tumor.
Researchers observed that tumors in androgen deficient male models grew more aggressively compared to those with normal hormone levels. Interestingly, female models did not show the same reaction to testosterone changes.
The findings suggest testosterone may play an unexpected protective role in the male brain during glioblastoma progression.
To better understand whether these findings applied to humans, scientists analyzed data from more than 1,300 men with glioblastoma using the Surveillance, Epidemiology, and End Results Program database.
The analysis showed that men receiving supplemental testosterone for unrelated medical reasons had a 38 percent lower risk of death compared to patients who were not taking testosterone therapy.
Although the researchers emphasized that this does not prove testosterone directly improves survival, the connection was strong enough to support further clinical investigation.
The team now believes future human trials are necessary to determine whether testosterone based therapies could help certain glioblastoma patients.
For years, many researchers believed androgens might worsen cancer because some hormone sensitive cancers, such as prostate cancer, can grow in response to testosterone.
This new study highlights that the brain behaves differently from other organs. The immune system inside the brain is highly specialized, and hormone activity may influence tumor growth in unexpected ways.
The researchers explained that testosterone appears to help maintain healthier immune responses inside the brain. Without it, inflammation and stress signaling increase, potentially allowing tumors to escape immune detection.
This could reshape future cancer research involving sex hormones and neurological diseases.
One important implication of the study involves androgen deprivation therapy, commonly used to treat prostate cancer. Scientists now wonder whether reducing testosterone in some patients could unintentionally worsen glioblastoma outcomes.
Researchers say future studies should investigate whether hormone suppression therapies may carry additional risks for patients with brain tumors.
At the same time, testosterone supplementation could eventually become part of experimental glioblastoma treatment strategies if future clinical trials confirm the current findings.
Experts caution that much more research is needed before testosterone could be recommended as a treatment option. Clinical safety, dosage, long term effects, and patient selection would all require careful evaluation.
Dr. Anthony Letai from the National Cancer Institute described the findings as a welcome surprise that could lead to new treatment directions for a cancer known to affect men more severely.
Lead researcher Justin Lathia from Cleveland Clinic also emphasized the importance of understanding how the brain’s immune system responds to hormonal changes.
The researchers plan to continue studying how tumors trigger inflammation in separate regions of the brain and how hormonal pathways influence immune activity during cancer progression.
While the results are promising, experts stress that patients should not start or stop testosterone therapy based solely on this study. The research remains in early stages, and no official treatment guidelines have changed.
Patients with glioblastoma or hormone related conditions should always consult qualified healthcare professionals before making medical decisions.
Still, the study offers hope that future therapies targeting hormonal and immune pathways could improve survival outcomes for people facing this devastating disease.
Glioblastoma remains one of the most difficult cancers to treat successfully. Standard therapies often include surgery, radiation, and chemotherapy, but long term survival rates remain low.
Innovative research like this provides new insight into how biological sex differences and hormone activity may influence cancer behavior. Understanding these mechanisms may eventually help scientists create more personalized treatment strategies for patients.
The discovery that testosterone may suppress tumor growth rather than promote it represents a major shift in scientific thinking and could inspire entirely new approaches to brain cancer treatment in the coming years.
Juyeun Lee et al. Androgen loss accelerates brain tumor growth via HPA axis activation. Nature (2026). DOI: 10.1038/s41586-026-10451-5
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek guidance from a licensed healthcare provider regarding medical conditions, medications, or treatment decisions. Research findings discussed in this article are preliminary and may not apply to all patients.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.